by Michael May | Jun 9, 2026
Fifteen years ago, regenerative medicine in Canada stood at an inflection point. The science was world-class, the academic talent was undeniable, and the promise of cell and gene therapies was beginning to capture global attention. Yet there was a critical problem:...
by Tara Fernandez | Feb 20, 2020
Immunotherapies have been heralded as a revolutionary paradigm shift in how cancer is treated, thanks to the exceptional cancer-killing properties of checkpoint inhibitors and chimeric antigen receptor (CAR) T cells. Today, approved therapies Yescarta™ and Kymriah™,...
by Mark Curtis | Apr 25, 2016
Welcome to your Cell Therapy Deal Review for the month of March. Cellectis continues to differentiate through a collaboration with MabQuest. PCT formed a partnership with Japanese conglomerate Hitachi. Kite partnered with Roche’s Genentech on a program for lymphoma....
by Angela C. H. McDonald | Aug 13, 2012
It takes precision, focus and persistence to perfect the art of origami. So perhaps it is no accident that researchers have needed to apply the same skills to overcome challenges in siRNA delivery, right down to the folding. A couple of years ago, my fellow blogger...
by Paul Krzyzanowski | Jul 17, 2012
Faced with patent shortages to replace flagship products, Big Pharma is increasing investments in smaller biotech companies to capture innovations early. Most new companies wither and die if they run out of initial funds before they’re profitable. In biotech,...
Comments